ALSO NOTED: ReNeuron returns to market; Scientists urge Relenza stockpiles; CombiMatrix, Arizona State collaborate; and much mo

> ReNeuron, which works with adult stem cells, has returned to London's junior AIM market after a two-year absence. Story

> In an article in The Lancet, scientists are urging governments to stockpile GSK's Relenza to guard against an avian flu epidemic. Report

> Xenogen of Alameda, California, will raise $15 million in a private placement of common stock. Release

> CombiMatrix and the BioDesign Institute at Arizona State University will collaborate on a peptide array synthesizer. Release

And Finally… Nearly one-in-six US high school students suffer from asthma, according to a new federal study that suggests better ways to control the chronic lung condition. Article

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.